(Q43794742)

English

The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials

scientific article published on 11 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

0 references

The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials (English)

1 reference

Europe PubMed Central

26 November 2017

1

1 reference

Europe PubMed Central

26 November 2017

author name string

Li-Na Tang

2

1 reference

Europe PubMed Central

26 November 2017

Ai-Na He

3

1 reference

Europe PubMed Central

26 November 2017

Zan Shen

4

1 reference

Europe PubMed Central

26 November 2017

Yang Yao

5

1 reference

Europe PubMed Central

26 November 2017

publication date

11 October 2011

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

189

1 reference

Europe PubMed Central

26 November 2017

6

1 reference

Europe PubMed Central

26 November 2017

437-443

1 reference

Europe PubMed Central

26 November 2017

https://scigraph.springernature.com/pub.10.1007/s00408-011-9332-1

0 references

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00408-011-9332-1

21 January 2018

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

1 reference

https://pubmed.ncbi.nlm.nih.gov/21986852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneity testing in meta-analysis of genome searches

1 reference

https://pubmed.ncbi.nlm.nih.gov/21986852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21986852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21986852

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00408-011-9332-1

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43794742&oldid=2103395352"